{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:10:24Z","timestamp":1715551824888},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background and Purpose\u2014<\/jats:italic>\n            <\/jats:bold>\n            Antiplatelet agents are widely used in the secondary prevention of stroke and other vascular events. The purpose of this review is to give a perspective of the factors involved in clinical practice for selecting antiplatelet drugs appropriate to the patient population.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Summary of Review\u2014<\/jats:italic>\n            <\/jats:bold>\n            Aspirin remains the most popular drug, because it is modestly effective (\u224825% risk reduction); however, it has undesirable side effects that are sometimes serious. The nonaspirin compounds are marginally more effective but are much more expensive and subject to commercial pressures from industry. A completely new look at these compounds is necessary, rather than spending more precious resources on \u201cdrug wars\u201d that are expensive in time and money.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusion\u2014<\/jats:italic>\n            <\/jats:bold>\n            A \u201cpolypill\u201d has been previously proposed, and possibly a combination of drugs targeted at the major vascular risk factors that is given to patients within 24 hours of initial stroke symptoms and to clearly defined patient populations may prove a solution.\n          <\/jats:p>","DOI":"10.1161\/01.str.0000177887.14339.46","type":"journal-article","created":{"date-parts":[[2005,8,12]],"date-time":"2005-08-12T02:09:37Z","timestamp":1123812577000},"page":"2034-2036","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Antiplatelet Agents in Secondary Prevention of Stroke"],"prefix":"10.1161","volume":"36","author":[{"given":"John W.","family":"Norris","sequence":"first","affiliation":[{"name":"From the Division of Clinical Neuroscience, St Georges Hospital Medical School, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(54)90544-9"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.3.6.468"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.15.1867"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.483S"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.2.255"},{"key":"e_1_3_2_7_2","unstructured":"Easton JD. Antiplatelet therapy in \u2018Stroke Prevention.\u2019 Norris JW Hachinski V eds. Oxford: Oxford University Press; 2001."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520420037035"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12228-3"},{"key":"e_1_3_2_10_2","first-page":"2238","volume":"35","year":"2004","unstructured":"Chaturvedi S. \u201cLacunarization\u201d of stroke prevention studies. Stroke. 2004; 35: 2238\u20132239.","journal-title":"Stroke"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.22.2901"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.37991.635266.44"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-5-200503010-00012"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000046583.40125.20"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.5.791"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMlim042229"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00887-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048264"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1419"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09358-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000185799.22645.8a"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.0000177887.14339.46","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T21:40:39Z","timestamp":1715550039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.0000177887.14339.46"}},"subtitle":["A Perspective"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1161\/01.STR.0000177887.14339.46"],"URL":"https:\/\/doi.org\/10.1161\/01.str.0000177887.14339.46","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"2005-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-07-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}